FindTrial
Sign In

Research blood draw

PROCEDURE12 trials

Sponsors

Washington University School of Medicine, Johns Hopkins University, National Heart, Lung, and Blood Institute (NHLBI)

Conditions

Abdominal CancerBeta-thalassemiaBreast CancerBreast CarcinomaCancer of BreastCancer of the PancreasCutaneous AngiosarcomaGlioblastoma

Phase 1

Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma
TerminatedNCT03422094
Washington University School of MedicineGlioblastoma
Start: 2018-10-31End: 2020-12-31Updated: 2021-10-27
CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome
Active, not recruitingNCT03572764
Washington University School of MedicineMyelodysplastic Syndromes
Start: 2018-12-14End: 2027-03-25Updated: 2026-04-14
Induction Paclitaxel Followed by Concurrent Paclitaxel and Radiation Therapy for Cutaneous Angiosarcoma
Active, not recruitingNCT03921008
Washington University School of MedicineCutaneous Angiosarcoma
Start: 2019-05-21End: 2028-01-16Updated: 2026-01-21
Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors
RecruitingNCT07599176
National Heart, Lung, and Blood Institute (NHLBI)Beta-thalassemia, Sickle Cell Disease
Start: 2026-06-01End: 2035-06-30Target: 90Updated: 2026-05-20

Phase 2

Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer
CompletedNCT03007979
Washington University School of MedicineBreast Cancer, Breast Carcinoma, Cancer of Breast +1
Start: 2017-06-15End: 2023-03-31Updated: 2024-03-20
ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer
CompletedNCT03449901
Washington University School of MedicineSoft Tissue Sarcoma
Start: 2018-05-09End: 2022-07-08Updated: 2025-12-11
PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma
WithdrawnNCT03598816
Washington University School of MedicineRenal Cell Carcinoma
Start: 2020-08-31End: 2024-05-31Updated: 2020-08-13
Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma
Active, not recruitingNCT04331041
Washington University School of MedicineCancer of the Pancreas, Pancreas Adenocarcinoma, Pancreas Cancer
Start: 2021-08-24End: 2027-04-21Updated: 2026-05-08
Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients
TerminatedNCT04536077
Washington University School of MedicineCancer of the Pancreas, Pancreas Cancer, Pancreatic Cancer
Start: 2021-08-13End: 2023-11-21Updated: 2024-10-08

Unknown Phase

Palliative Lattice Stereotactic Body Radiotherapy (SBRT) for Patients With Sarcoma, Thoracic, Abdominal, and Pelvic Cancers
CompletedNCT04553471
Washington University School of MedicineAbdominal Cancer, Pelvic Cancer, Sarcoma +1
Start: 2020-09-22End: 2023-05-04Updated: 2024-08-29
A Low AGE (Advanced Glycation End-product) Dietary Intervention for Breast Cancer Survivors
CompletedNCT05265715
Washington University School of MedicineBreast Cancer
Start: 2022-10-14End: 2024-03-22Updated: 2025-01-08
Mood Alterations in the Patients With Non-Muscle Invasive Bladder Cancer Treated With BCG
RecruitingNCT05672615
Johns Hopkins UniversityNon-Muscle Invasive Bladder Cancer
Start: 2023-03-21End: 2028-03-31Target: 42Updated: 2025-11-18

Related Papers

A phase II study of stereotactic body radiotherapy and focal adhesion kinase inhibitor in advanced pancreatic adenocarcinoma.
Journal of Clinical Oncology2026-01-10
Abstract 1174: Incorporation of multisector analysis into the design of personalized DNA vaccines for patients with newly diagnosed glioblastoma
Cancer Research2024-03-221 citations
Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
Clinical Cancer Research2023-01-2444 citations
Combination treatment of radiofrequency ablation and peptide neoantigen vaccination: Promising modality for future cancer immunotherapy
Frontiers in Immunology2022-09-2926 citations
Stromal Reprogramming by FAK Inhibition Overcomes Radiation Resistance to Allow for Immune Priming and Response to Checkpoint Blockade
Cancer Discovery2022-09-2794 citations
Abstract P2-07-01: Blood tumor mutational burden (bTMB) and blood copy number burden (bCNB) by genome-wide circulating tumor DNA (ctDNA) assessment predict outcome and resistance in hormone-receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC) patients (pts) treated with CDK4/6 inhibitor (CDK4/6<i>i</i>)
Cancer Research2022-02-15
Abstract PO-112: Stromal reprogramming by FAK inhibition overcomes radiation resistance to allow for immune priming and response to checkpoint blockade
Cancer Research2021-11-15
A Pilot Study of CPX-351 (Vyxeos ©) for Transplant Eligible, Higher Risk Patients with Myelodysplastic Syndrome
Blood2021-11-058 citations
Phase II trial of pegylated arginine deiminase in combination with gemcitabine and docetaxel for the treatment of soft tissue sarcoma.
Journal of Clinical Oncology2021-05-209 citations
Abstract PS12-02: Safety and efficacy of an alternative schedule of palbociclib (PAL) in hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC) and the utility of serum thymidine kinase 1 (sTK1) activity in predicting PAL response
Cancer Research2021-02-15
Concurrent paclitaxel and radiation therapy for the treatment of cutaneous angiosarcoma.
2021-01-2810 citations
Spatially fractionated stereotactic body radiation therapy (Lattice) for large tumors
Advances in Radiation Oncology2021-01-1084 citations
Abstract P1-19-13: A phase II trial assessing the safety of an alternative dosing schedule of palbociclib (palbo) in hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC): Alt Dose Palbo
Cancer Research2020-02-154 citations
Abstract CT111: Preclinical justification for the Phase II clinical trial ADI-PEG 20 in combination with gemcitabine and docetaxel for the treatment of soft tissue sarcoma
Clinical Trials2019-07-01
Abstract CT111: Preclinical justification for the Phase II clinical trial ADI-PEG 20 in combination with gemcitabine and docetaxel for the treatment of soft tissue sarcoma
Cancer Research2019-07-01
A phase II study of ADI-PEG 20 in combination with gemcitabine and docetaxel for the treatment of soft tissue sarcoma.
Journal of Clinical Oncology2019-05-20